Granted Patent
B2
US 12,378,298 · App. 17/357,780 · Granted Aug 5, 2025
T cell receptor
Inventors:
Hans Stauss (London, GB); Sharyn Thomas (London, GB); Ben Willcox (Birmingham, GB); Fiyaz Mohammed (Birmingham, GB)
Assignee:
UCL BUSENESS LTD
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the α chain; R9 of the β chain; Y10 of the β chain; T24 of the α chain; V19 of the α chain; T20 of the α chain; M50 of the α chain; T5 of the α chain; Q8 of the α chain; S86 of the α chain; F39 of the α chain; D55 of the α chain; R43 of the β chain; A66 of the α chain; V19 of the β chain; L21 of the β chain; L103 of the β chain; T3 of the α chain; S7 of the α chain; P9 of the α chain; M11 of the α chain; A16 of the α chain; T18 of the α chain; L21 of the α chain; S22 of the α chain; D26 of the α chain; F40 of the α chain; S47 of the α chain; R48 of the α chain; Q49 of the α chain; I51 of the α chain; L52 of the α chain; V53 of the α chain; T67 of the α chain; E68 of the α chain; N74 of the α chain; F76 of the α chain; N79 of the α chain; Q81 of the α chain; A83 of the α chain; K90 of the α chain; S92 of the α chain; D93 of the α chain; and M101 of the α chain; wherein the at least one amino acid residue is not present in the corresponding germline TCR amino acid sequence.
Claims (9)
1. A method for increasing the cell surface expression of a TCR, comprising
(i) providing a TCR α chain and β chain sequence;
(ii) determining an amino acid residue of the TCR α chain and β chain at positions 96 of the α chain and 10 of the β chain; and
(iii) altering the amino acid residue at the positions listed in step (ii) to L96 of the α chain and Y10 of the β chain.
2. The method for increasing the cell surface expression of a TCR of claim 1 , wherein altering the amino acid residue is by PCR mutagenesis of a nucleic acid sequence encoding the TCR.
3. A method for increasing the cell surface expression of a TCR, comprising:
(i) providing a TCR α chain and β chain sequence;
(ii) determining an amino acid residue of the TCR α chain and β chain at a plurality of positions comprising 96 of the α chain and 10 of the β chain; and
(iii) altering the amino acid residue at a plurality of the positions listed in step (ii) to an amino acid residue comprising L96 of the α chain and Y10 of the β chain.
Assignments (2)
CHANGE OF NAME
Recorded Dec 6, 2021
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 058314/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 6, 2021
From: STAUSS, HANS; THOMAS, SHARYN; WILLCOX, BEN; MOHAMMED, FIYAZ
To: UCL BUSINESS PLC
Reel/Frame 058318/0414 →
Priority Claims (1)
GB 1506642
· Apr 20, 2015
· national
Continuity (2)
Division
15568440
References Cited (67)
US 20100297093A1
· Robbins et al.
· 2010
[cited by applicant]
US 20180251513A1
· Stauss et al.
· 2018
[cited by applicant]
US 20190048085A1
· Dotti et al.
· 2019
[cited by applicant]
US 20190336531A1
· Stauss et al.
· 2019
[cited by applicant]
US 20220267406A1
· Stauss et al.
· 2022
[cited by applicant]
EP 3015477A1
· 2016
[cited by applicant]
WO WO2005113595A2
· 2005
[cited by examiner]
WO WO2006029010A2
· 2006
[cited by applicant]
WO WO2011001152A1
· 2011
[cited by applicant]
WO WO2012013913A1
· 2012
[cited by applicant]
WO WO2014160030A2
· 2014
[cited by applicant]
WO WO2014206304A1
· 2014
[cited by applicant]
WO WO2016007570A2
· 2016
[cited by applicant]
WO WO2016170320A1
· 2016
[cited by applicant]
WO WO2018073595A1
· 2018
[cited by applicant]
WO WO2018073596A2
· 2018
[cited by applicant]
WO 2021023996A2
· 2021
[cited by applicant]
Coffin, J.M. et al., Retroviruses. New York: Cold Spring Harbor Laboratory Press, 1997; pp. 758-763.
[cited by applicant]
Donnelly, M. et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” Journal of General Virology, 82:1027-1041 (2001).
[cited by applicant]
Fernandez, C.S. et al., “Ex-vivo alpha-galactosylceramide activation of NKT cells in humans and macaques,” Journal of Immunological Methods, 382:150-159 (2012).
[cited by applicant]
Folch, G & Lefranc, M.P., “The human T cell receptor beta variable (TRBV) genes,” Exp Clin Immunogenet, 17:42-54 (2000).
[cited by applicant]
Godfrey, D.I. et al., “Going both ways: Immune regulation via CD1d-dependent NKT cells,” Journal of Clinical Investigation, 114(10):1379-1388 (2004).
[cited by applicant]
Govers, C. et al. (Feb. 1, 2010) “T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing”, Trends Mol Med, 16(2):77-87.
[cited by applicant]
Henel, G. et al., “Basic Theory and Clinical Applications of Flow Cytometry,” Lab Medicine, 38(7):428-436 (2007).
[cited by applicant]
Henikoff, S. et al., “Amino acid substitution matrices from protein blocks,” Proc Natl Acad Sci USA, 89:10915-10919 (1992).
[cited by applicant]
Hodges, E. et al., “Diagnostic role of tests for T cell receptor (TCR) genes,” J Clin Pathol., 56(1):1-11 (2003).
[cited by applicant]
International Preliminary Report on Patentability, PCT/GB2016/051084, dated Jul. 28, 2017, 68 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/GB2016/051084, dated Jun. 7, 2016, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/GB2017/053167, dated Apr. 23, 2019, 11 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/GB2017/053167, dated Mar. 26, 2018, 17 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/GB2017/053168, dated Apr. 23, 2019, 11 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/GB2017/053168, dated Apr. 16, 2018, 17 pages.
[cited by applicant]
Jiang, Z-M et al., “Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen”, Journal of Translational Medicine, 13:141, 10 pages (2015).
[cited by applicant]
Koop, B.F. et al., “The human T-cell receptor TCRAC/TCRDC (C alpha/C delta) region: Organization, sequence and evolution of 97.6 kb of DNA,” Genomics, 19:478-493 (1994).
[cited by applicant]
Lefranc, M-P. et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and lg superfamily V-like domains,” Developmental & Comparative Immunology, 27(Issue 1):55-77 (2003).
[cited by applicant]
Lewis, P. et al., “Human immunodeficiency virus infection of cells arrested in the cell cycle,” Embo J., 11(8):3053-3058 (1992).
[cited by applicant]
Macdonald, H.R., “NKT cells: In the beginning,” Eur J Immunol, 37 (Suppl):S111-S115 (2007).
[cited by applicant]
Okamoto, S. et al. (Dec. 18, 2012) “A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression”, Mol Ther Nucleic Acids, 1(12):e63, doi: 10.103…
[cited by applicant]
Okamoto, S. et al. (Dec. 1, 2009) “Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR” AACR Annual Meeting, Apr. 14-18, 2018, Chicago, IL. C…
[cited by applicant]
Pan, Jianping and Chuansen, S. (2006) Medical Immunology. Zhejian University Press; pp. 179-180 (Chinese); and English translation, 4 pages.
[cited by applicant]
Papworth, C. et al. (1994) “Highly Efficient Double-Stranded, Site-Directed Mutagenesis with the Chameleon Kit” Strategies in Mol Biol, 7:38-40.
[cited by applicant]
Reinherz, E.L. et al. (Dec. 1999) “The Crystal Structure of a T Cell Receptor in Complex with Peptide and MHC Class II” Science, 286(5446):1913-1921.
[cited by applicant]
Reiser, J.B. et al. (Oct. 2000) “Crystal structure of a T cell receptor bound to an allogenic MHC molecule” Nature Immunology, 1:291-297, with Erratum.
[cited by applicant]
Richman, S.A. et al. (Feb. 2009) “Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments” Molecular Immunology, 46(5):902-916.
[cited by applicant]
Robbins, P.F. et al. (May 1, 2008) “Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions” J Immunol, 180(9):6116-6131.
[cited by applicant]
Rowen, L. et al. (Jun. 1996) “The complete 685-kilobase DNA sequence of the human beta T cell receptor locus” Science, 272(5269):1755-1762.
[cited by applicant]
Scaviner, D. et al. (2000) “The Human T Cell Receptor Alpha Variable (TRAV) Genes” Exp Clin Immunogenet, 17:83-96.
[cited by applicant]
Sethi, D.K. et al. (Jan. 2011) “A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC” J Exp Med, 208(1):91-102.
[cited by applicant]
Shapiro, H.M., “Practical Flow Cytometry,” John Wiley & Sons (2003).
[cited by applicant]
Smith, D.J. et al. (Feb. 2015) “Genetic engineering of hematopoietic stem cells to generate invariant natural killer T Cells” Proceedings National Academy of Sciences USA, 112(5):1523-1528.
[cited by applicant]
Sommermeyer, D. et al. (Jun. 1, 2010) “Minimal Amino Acid Exchange in Human TCR Constant Regions Fosters Improved Function of TCR Gene-Modified TCells” J Immunol, 184(11):6223-6231.
[cited by applicant]
Zhou, D. et al. (Mar. 2006) “High throughput analysis of TCR-beta rearrangement and gene expression in single T cells” Laboratory Investigation, 86:314-321.
[cited by applicant]
Aggen et al. “Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors” Protein Engineering, Design & Selection, vol. 24, No. 4, pp. 361-372, Apr. 2011.
[cited by applicant]
Declaration of Non-Establishment of International Search Report and Written Opinion, issued in International Patent Application No. PCT/GB2020/051881, mailed Dec. 18, 2020, 9 pages.
[cited by applicant]
Kieke et al. “Selection of functional T cell receptor mutants from a yeast surface-display library” Proc. Natl. Acad. Sci. USA, vol. 96, pp. 5651-5656, May 1999.
[cited by applicant]
Shusta et al. “Directed evolution of a stable scaffold for T-cell receptor engineering” Nature Biotechnology, vol. 18, pp. 754-759, Jul. 2000.
[cited by applicant]
U.S. Appl. No. 15/568,440, by Stauss: Final Office Action, dated Feb. 24, 2021; 22 pages.
[cited by applicant]
U.S. Appl. No. 15/568,440, by Stauss: Non-Final Office Action, dated Jul. 21, 2020; 17 pages.
[cited by applicant]
U.S. Appl. No. 15/568,440, by Stauss: Restriction Requirement, dated Dec. 27, 2019; 8 pages.
[cited by applicant]
Uddin, Imran, et al. “An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood” Methods Mol Biol, vol. 1884, pp. 15-42, 2019.
[cited by applicant]